Language:

Conversion to Aflibercept After Prior Anti-VEGF Therapy for Persistent Diabetic Macular Edema

American journal of ophthalmology, 2016-04, Vol.164, p.118-127.e2 [Peer Reviewed Journal]

Elsevier Inc. ;2016 Elsevier Inc. ;Copyright © 2016 Elsevier Inc. All rights reserved. ;Copyright Elsevier Limited Apr 2016 ;ISSN: 0002-9394 ;EISSN: 1879-1891 ;DOI: 10.1016/j.ajo.2015.12.030 ;PMID: 26748058 ;CODEN: AJOPAA

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Conversion to Aflibercept After Prior Anti-VEGF Therapy for Persistent Diabetic Macular Edema
Author: Rahimy, Ehsan ; Shahlaee, Abtin ; Khan, M. Ali ; Ying, Gui-shuang ; Maguire, Joseph I ; Ho, Allen C ; Regillo, Carl D ; Hsu, Jason
Subjects: Adult ; Aged ; Aged, 80 and over ; Angiogenesis Inhibitors - therapeutic use ; Bevacizumab - therapeutic use ; Cataracts ; Clinical trials ; Diabetes ; Diabetic retinopathy ; Diabetic Retinopathy - diagnosis ; Diabetic Retinopathy - drug therapy ; Diabetic Retinopathy - physiopathology ; Drug Substitution ; Edema ; Eye surgery ; FDA approval ; Female ; Follow-Up Studies ; Generalized linear models ; Health Insurance Portability & Accountability Act 1996-US ; Humans ; Integrated software ; Intraocular Pressure - drug effects ; Intravitreal Injections ; Macular degeneration ; Macular Edema - diagnosis ; Macular Edema - drug therapy ; Macular Edema - physiopathology ; Male ; Middle Aged ; Ophthalmology ; Pharmaceutical industry ; Ranibizumab - therapeutic use ; Receptors, Vascular Endothelial Growth Factor - therapeutic use ; Recombinant Fusion Proteins - therapeutic use ; Retina - pathology ; Retrospective Studies ; Standard deviation ; Statistical analysis ; Surgery ; Tomography, Optical Coherence ; Vascular endothelial growth factor ; Vascular Endothelial Growth Factor A - antagonists & inhibitors ; Visual Acuity - drug effects
Is Part Of: American journal of ophthalmology, 2016-04, Vol.164, p.118-127.e2
Description: Purpose To evaluate the short-term functional and anatomic outcomes of patients with persistent diabetic macular edema (DME) who were converted from bevacizumab and/or ranibizumab to aflibercept. Design Retrospective, interventional, noncomparative, consecutive case series. Methods Only eyes treated with at least 4 consecutive injections of ranibizumab/bevacizumab spaced 4–6 weeks apart prior to conversion and with at least 2 aflibercept injections afterward were considered for inclusion. Pertinent patient demographic, examination, and treatment data were extracted from clinical charts and tabulated for analysis. Results Fifty eyes of 37 patients were included. Eyes received a mean of 13.7 bevacizumab/ranibizumab injections prior to conversion, followed by 4.1 aflibercept injections over 4.6 months of subsequent follow-up. The mean logMAR visual acuity at the pre-switch visit was 0.60 ± 0.43 (Snellen equivalent, 20/80). This improved to 0.55 ± 0.48 (Snellen equivalent, 20/70) by the second visit after conversion, corresponding to a mean logMAR change of −0.05 ± 0.22 ( P = .12). The average central macular thickness from the pre-switch spectral-domain optical coherence tomography scan was 459.2 ± 139.2 μm. This significantly improved to 348.7 ± 107.8 μm by the second visit following conversion, reflecting a mean decrease of 112 ± 141 μm ( P < .0001). The mean intraocular pressure (IOP) recorded at the pre-switch visit was 15.1 ± 3.3 mm Hg. At the second follow-up after converting to aflibercept, the IOP averaged 14.9 ± 3.2 mm Hg, with a mean decrease of 0.2 ± 3.0 mm Hg ( P = .63). Conclusions Conversion to aflibercept for persistent DME resulted in significant anatomic improvements. While trends towards improved visual acuity and reduction in IOP were observed, these were not statistically significant.
Publisher: United States: Elsevier Inc
Language: English
Identifier: ISSN: 0002-9394
EISSN: 1879-1891
DOI: 10.1016/j.ajo.2015.12.030
PMID: 26748058
CODEN: AJOPAA
Source: MEDLINE
Alma/SFX Local Collection

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Conversion to Aflibercept After Prior Anti-VEGF Therapy for Persistent Diabetic Macular Edema

Elsevier Inc. ;2016 Elsevier Inc. ;Copyright © 2016 Elsevier Inc. All rights reserved. ;Copyright Elsevier Limited Apr 2016 ;ISSN: 0002-9394 ;EISSN: 1879-1891 ;DOI: 10.1016/j.ajo.2015.12.030 ;PMID: 26748058 ;CODEN: AJOPAA

Searching Remote Databases, Please Wait